Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Loxoprofen Sodium Eye Drops for Postoperative Inflammation and Pain After Cataract Surgery
CTR20222801Phase 2Completed
- Sponsor
- Guangzhou Aobo Pharmaceutical Technology
- Start
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in post-operative inflammation, postoperative pain and cataract comparing Loxoprofen Sodium Eye Drops with Placebo (2 arms). Primary endpoint: Proportion of subjects with Anterior Chamber Cells (ACC) and Anterior Chamber Flare (ACF) grades of 0 at Day 15 post-op. Started Oct 2022; status: completed.
02
Drugs
loxoprofen
03
Conditions
post-operative inflammationpostoperative paincataract
Beyond the preview
Go deeper on CTR20222801.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222801.